Clinical study of naftopidil,a new type of ?_1-adrenoceptor antagonist for treatment of benign prostatic hyperplasia
- VernacularTitle:新型?_1-肾上腺素能受体阻滞剂萘哌地尔治疗良性前列腺增生的临床研究
- Author:
Ningchen LI
;
Xiaochun ZHANG
;
Xiaofeng WANG
- Publication Type:Journal Article
- Keywords:
Naftopidil;
Adrenergic alpha-antagonists;
Clinical trials,phase Ⅱ;
Benign prostatic hyperplasia
- From:
Chinese Journal of Urology
2001;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the efficacy and safety of naftopidil,a new ? 1-adrenoceptor antagonist for treatment of benign prostatic hyperplasia(BPH). Methods A randomized,double-blind,double-simulant,parallel-controlled,multicentral clinical trial was conducted in 224 patients with BPH.Patients of treatment group received naftopidil (25 mg,once a day) and the controls received tamsulosin (0.2 mg,once a day). Results After 6-week therapy,IPSS,quality of life (QOL) score,maximum urinary flow rate (Qmax) and average urinary flow rate(Qave) were significantly improved both in naftopidil group and tamsulosin (control) group.In naftopidil group,IPSS was averagely decreased by 11.03 (P0.05).The clinical adverse event rate was 2.68% in naftopidil group, which was significantly lower than that in tamsulosin group (8.93%,P
